A Second Discussion With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.

Executed on:Feb 2, 2024 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Ascension HealthSenior Director of Clinical Drug Management and Pharmacy Benefits Programs
Two decades of experience in clinical drug management and optimizing pharmacy benefits programs for leading healthcare organizations.
Responsible for overseeing all aspects of formulary management, prior authorization, drug utilization review, and medication therapy management programs.

Interview Goal

This conversation seeks to better understand how payors think about generic drugs when the branded reference drug is part of a closed loop distribution system. Key areas of focus will be:
What are the impacts on timing of generic conversion in these systems?
Are Generics responsible for more support if launching a product that has a patient support hub/speciality pharmacy distribution model.
How effective a strategy to stave off generics is this model historically? Specifically prior to ANDA filing and after FDA approval

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.